ES2326348R - USE OF AGONIST COMPOUND OF THE TACTICAL ACTIVITY TUBULINA DEACETILASA OF THE HDAC6 PROTEIN IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND ITS APPLICATIONS IN THE TREATMENT OF VIRAL INFECTIONS. - Google Patents
USE OF AGONIST COMPOUND OF THE TACTICAL ACTIVITY TUBULINA DEACETILASA OF THE HDAC6 PROTEIN IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND ITS APPLICATIONS IN THE TREATMENT OF VIRAL INFECTIONS.Info
- Publication number
- ES2326348R ES2326348R ES200602025A ES200602025A ES2326348R ES 2326348 R ES2326348 R ES 2326348R ES 200602025 A ES200602025 A ES 200602025A ES 200602025 A ES200602025 A ES 200602025A ES 2326348 R ES2326348 R ES 2326348R
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical compositions
- viral infections
- treatment
- applications
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 102100022537 Histone deacetylase 6 Human genes 0.000 title abstract 4
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 title abstract 4
- 208000036142 Viral infection Diseases 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 abstract 3
- 238000013459 approach Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 102000004243 Tubulin Human genes 0.000 abstract 1
- 108090000704 Tubulin Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000021736 acetylation Effects 0.000 abstract 1
- 238000006640 acetylation reaction Methods 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000006196 deacetylation Effects 0.000 abstract 1
- 238000003381 deacetylation reaction Methods 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Uso de compuestos agonistas de la actividad tubulina desacetilasa de la proteína HDAC6 en la elaboración de composiciones farmacéuticas, dichas composiciones farmacéuticas y sus aplicaciones en el tratamiento de infecciones virales.<br /><br />La presente invención se basa en el hecho de que el equilibrio de la acetilación/desacetilación de los microtúbulos es clave para modular la entrada de virus fusogénicos en las células eucariotas, preferentemente la entrada del virus VIH-1 en las células T, y que está regulado por la proteína HDAC6, lo que permite definir nuevas aproximaciones terapéuticas para la profilaxis y tratamiento de infecciones virales. Estas aproximaciones terapéuticas se basan en el uso de compuestos activadores de la actividad de dicha proteína HDAC6 y de las composiciones farmacéuticas que los contienen en métodos de tratamiento de dichas infecciones virales.Use of agonist compounds of the HDAC6 protein tubulin deacetylase activity in the preparation of pharmaceutical compositions, said pharmaceutical compositions and their applications in the treatment of viral infections. <br /> <br /> The present invention is based on the fact that that the balance of the acetylation / deacetylation of microtubules is key to modulate the entry of spherogenic viruses into eukaryotic cells, preferably the entry of HIV-1 virus into T cells, and that it is regulated by the HDAC6 protein, which allows define new therapeutic approaches for the prophylaxis and treatment of viral infections. These therapeutic approaches are based on the use of activating compounds of the activity of said HDAC6 protein and of the pharmaceutical compositions containing them in methods of treating said viral infections.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200500953A ES2275400B1 (en) | 2005-04-20 | 2005-04-20 | USE OF AGONIST COMPOUNDS OF THE TACTICAL ACTIVITY TUBULINA DEACETILASA PROTEIN HDAC6 IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND ITS APPLICATIONS IN THE TREATMENT OF VIRAL INFECTIONS. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ES2326348A2 ES2326348A2 (en) | 2009-10-07 |
| ES2326348R true ES2326348R (en) | 2009-11-12 |
| ES2326348B1 ES2326348B1 (en) | 2010-09-22 |
Family
ID=37114737
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200500953A Expired - Fee Related ES2275400B1 (en) | 2005-04-20 | 2005-04-20 | USE OF AGONIST COMPOUNDS OF THE TACTICAL ACTIVITY TUBULINA DEACETILASA PROTEIN HDAC6 IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND ITS APPLICATIONS IN THE TREATMENT OF VIRAL INFECTIONS. |
| ES200602025A Active ES2326348B1 (en) | 2005-04-20 | 2006-07-27 | USE OF AGONIST COMPOUNDS OF THE TACTICAL ACTIVITY TUBULINA DEACETILASA PROTEIN HDAC6 IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND ITS APPLICATIONS IN THE TREATMENT OF VIRAL INFECTIONS. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200500953A Expired - Fee Related ES2275400B1 (en) | 2005-04-20 | 2005-04-20 | USE OF AGONIST COMPOUNDS OF THE TACTICAL ACTIVITY TUBULINA DEACETILASA PROTEIN HDAC6 IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND ITS APPLICATIONS IN THE TREATMENT OF VIRAL INFECTIONS. |
Country Status (2)
| Country | Link |
|---|---|
| ES (2) | ES2275400B1 (en) |
| WO (1) | WO2006111596A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2100879A1 (en) | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
| US20110195432A1 (en) * | 2008-10-14 | 2011-08-11 | Joshi Alumkal | Methods for the selection of therapeutic treatments for cancer |
| US20170137824A1 (en) * | 2014-06-13 | 2017-05-18 | Indranil BANERJEE | New treatment against influenza virus |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69119700T2 (en) * | 1990-11-07 | 1996-11-07 | Hoechst Roussel Pharma | Use of xanthines in the manufacture of medicaments to inhibit the proliferation of human retroviruses |
| US20030129724A1 (en) * | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| GB0005199D0 (en) * | 2000-03-04 | 2000-04-26 | Imp College Innovations Ltd | Modulation of histone deacetylase |
-
2005
- 2005-04-20 ES ES200500953A patent/ES2275400B1/en not_active Expired - Fee Related
-
2006
- 2006-04-20 WO PCT/ES2006/000192 patent/WO2006111596A1/en not_active Ceased
- 2006-07-27 ES ES200602025A patent/ES2326348B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2275400A1 (en) | 2007-06-01 |
| ES2275400B1 (en) | 2008-04-01 |
| ES2326348B1 (en) | 2010-09-22 |
| WO2006111596A1 (en) | 2006-10-26 |
| ES2326348A2 (en) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022000503A2 (en) | Compounds Useful for Treating Influenza Virus Infections | |
| CL2022003733A1 (en) | 1'-cyano nucleoside analogues and uses thereof | |
| AR052771A1 (en) | HCV INHIBITING BICYCLE PYRIMIDINS | |
| DOP2023000037A (en) | PHOSPHOLIPIDS COMPOUNDS AND THEIR USES | |
| CL2024001186A1 (en) | Phospholipid compounds and their uses | |
| MX2022002740A (en) | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES. | |
| BR112015011760A2 (en) | compound, use of the compound, and use of a pharmaceutical composition | |
| CL2018003135A1 (en) | Aromatic derivatives of sulfonamide. | |
| CL2017003436A1 (en) | Benzoxacepin oxazolidinone compounds and methods of use | |
| SV2006002347A (en) | PIRIDAZINONA COMPOUNDS | |
| PE20180160A1 (en) | SULFONYLUREAS AND RELATED COMPOUNDS AND THE USE OF THEM | |
| CY1122792T1 (en) | MONO-OR DISUBTITUTED INDOLE DERIVATIVES AS DANGE VIRUS REPLICATION INHIBITORS | |
| DOP2025000244A (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | |
| UY37646A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
| AR070026A1 (en) | SET OF ELEMENTS FOR THE DOSAGE OF 1-AMINO-ALQUILCICLOHEXANOS, SUCH AS NERAMEXAN, AND TREATMENT OF DIFFERENT DISEASES INCLUDING TINNITUS | |
| EA200901080A1 (en) | NEW NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF VIRAL INFECTIONS | |
| CO2020013834A2 (en) | Certain Pladienolide Compounds and Methods of Use | |
| DOP2024000171A (en) | ANTIVIRAL COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | |
| CO2024011995A2 (en) | Antiviral compounds and methods of their preparation and use | |
| CL2009000599A1 (en) | Compounds derived from substituted 4,5-dihydro-1h-pyrazol (4,3-g) benzothiazole; pharmaceutical composition; Useful for the treatment and prevention of cancer, infections, inflammatory and autoimmune diseases, among others. | |
| ES2326348R (en) | USE OF AGONIST COMPOUND OF THE TACTICAL ACTIVITY TUBULINA DEACETILASA OF THE HDAC6 PROTEIN IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND ITS APPLICATIONS IN THE TREATMENT OF VIRAL INFECTIONS. | |
| EP4285910A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NERVE INFECTIONS WITH ELEUTHEROSIDE B AS ACTIVE INGREDIENT | |
| EA202190766A1 (en) | IMMUNOMODULATORS, THEIR COMPOSITIONS AND METHODS OF APPLICATION | |
| EP4452295A4 (en) | Pharmaceutical composition for the treatment of viral infections | |
| CY1124906T1 (en) | PHENYLDIFLUOROMETHYL SUBSTITUTED PROLINAMIDE COMPOUND |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20091007 |
|
| FG2A | Definitive protection |
Ref document number: 2326348B1 Country of ref document: ES |